Clinical trial NCT05933148: Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
Official title: Network-based Real-time Neurofeedback Using Ultra-high Field MRI to Reduce Rumination Levels in Depression
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Major Depressive Disorder
Lead sponsor: Icahn School of Medicine at Mount Sinai
Sponsor class: OTHER
First posted: 2023-07-06
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Single-blind sham-controlled randomized trial
Primary purpose: TREATMENT

Brief summary: Patients with major depressive disorder (MDD) exhibit increased levels of rumination (i.e. repetitive thinking and focus on negative mood states) which have been found to increase the risk of depressive relapse. The ability to reduce rumination levels among these patients is greatly needed. Rumination is known to be associated with the default mode network (DMN) region activity. Implementing the Dependency Network Analysis (DEPNA), a recently developed method by the research team to quantify the connectivity influence of network nodes, found that rumination was significantly associated with lower connectivity influence of the left medial orbitofrontal cortex (MOFC) on the right precuneus, both key regions within the DMN. This study implements the first real-time fMRI neurofeedback (Rt-fMRI-NF) network-based protocol for up-regulation of the MOFC influence on the precuneus in patients with MDD to reduce rumination levels. This will allow for more accurate explicit brain connections modulation than the standard single brain region activity; creating a larger opportunity for target clinical neuromodulation treatment in individuals with MDD.

Detailed description: Major depressive disorder (MDD) is the world's largest health problem, and current available treatments fail at relieving symptoms for many patients. Rumination, which is conceptualized as repetitive thinking and focus on one's distress and negative mood states is a core feature of MDD. Patients with MDD exhibit increased levels of rumination which have been found to increase the risk of depressive relapse in remitted patients. The ability to reduce rumination levels among these patients is greatly needed.

Neurofeedback (NF) is a technique that feeds back information about brain signals to the individual in real-time, to allow for implicit modulation of the brain signal in order to improve performance. Yet, classic real-time fMRI-NF protocols focus on single region activity neglecting to consider the neural network dynamics, accounting for direct influences between regions.

Implementing the Dependency Network Analysis (DEPNA), a method developed by the research team, tested whether network connectivity influences during resting-state functional MRI (fMRI) are associated with rumination in patients with MDD. The research team found that rumination was significantly associated with lower connectivity influence of the left medial orbito-frontal cortex (MOFC) on the right precuneus, both key regions within the DMN. This is in line with intracranial recordings studies showing that MOFC activity precedes the precuneus in response to emotional stimuli.

The research team intend to extend this work by conducting the first real-time fMRI neurofeedback (Rt-fMRINF) protocol for up-regulation of the MOFC influence on the precuneus in patients with MDD and healthy controls to reduce rumination levels. The research team aims to develop an advanced ultra-high field MRI protocol that will allow for rt-fMRI-NF derived from networks' connectivity features as constructed by the DEPNA, and thus training the subject to control explicit brain connections. Specifically, the research team aims to train MDD patients to better regulate rumination levels by upregulating the influence of the MOFC on the precuneus.

Eligibility criteria: Inclusion Criteria:

* Male or female aged 18-65 years who either meet DSM-5 Axis Disorders (SCID) or the Mini International Neuropsychiatric Interview (MINI) for major depressive disorder (MDD) with a current major depressive episode OR does not meet for any current or past psychiatric diagnoses
* Participants must have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the informed consent process

Exclusion Criteria:

* Any current or history of schizophrenia or other psychotic disorder, neurodevelopmental disorder, or neurocognitive disorder for patients, active substance use disorder within the past 6 months
* Unstable medical illness, concomitant use of any medication with central nervous system activity within 1 week of MRI scan
* Pregnancy
* Patients who are currently hospitalized in the inpatient psychiatric units at Mount Sinai Hospital or involuntarily admitted/court-ordered
* Subjects judged to be at serious and imminent suicidal or homicidal risk by the study-affiliated psychiatrist or another MD, and contradictions to MRI

Primary outcomes:
measure: Change in Self-reported rumination related to negative affect as measured by Rumination Response Style (RRS)
timeFrame: Pre-Neurofeedback (day 0) and Post-Neurofeedback (MRI assessment day 1)
Secondary outcomes:
measure: Self-reported rumination related to negative affect as measured by Rumination Response Style (RRS)
timeFrame: Pre-MRI Scan at screening (day 0)
measure: Self-reported rumination related to negative affect as measured by Rumination Response Style (RRS)
timeFrame: Post-MRI scan at follow up visit 24 hours
measure: Self-reported rumination related to negative affect as measured by Rumination Response Style (RRS)
timeFrame: Post-MRI scan at follow up visit day 7
measure: Self-reported rumination related to negative affect as measured by Rumination Response Style (RRS)
timeFrame: Post-MRI scan at follow up visit day 30
measure: Self-reported rumination related to negative affect as measured by Perceive Stress Scale (PSS)
timeFrame: Pre-MRI Scan at screening (day 0)
measure: Self-reported rumination related to negative affect as measured by Perceive Stress Scale (PSS)
timeFrame: Post-MRI scan at follow up visit 24 hours
measure: Self-reported rumination related to negative affect as measured by Perceive Stress Scale (PSS)
timeFrame: Post-MRI scan at follow up visit day 7
measure: Self-reported rumination related to negative affect as measured by Perceive Stress Scale (PSS)
timeFrame: Post-MRI scan at follow up visit day 30
measure: Self-reported rumination related to negative affect as measured by Quick Inventory of Depressive Symptomatology (QIDS)
timeFrame: Pre-MRI scan at screening (day 0)
measure: Self-reported rumination related to negative affect as measured by Quick Inventory of Depressive Symptomatology (QIDS)
timeFrame: Post-MRI scan at follow up visit 24 hours
measure: Self-reported rumination related to negative affect as measured by Quick Inventory of Depressive Symptomatology (QIDS)
timeFrame: Post-MRI scan at follow up visit day 7
measure: Self-reported rumination related to negative affect as measured by Quick Inventory of Depressive Symptomatology (QIDS)
timeFrame: Post-MRI scan at follow up visit day 30
measure: Self-reported rumination related to negative affect as measured by Montgomery-Asberg Depression Rating Scale (MADRS)
timeFrame: Pre-MRI scan at screening (day 0)
measure: Self-reported rumination related to negative affect as measured by Montgomery-Asberg Depression Rating Scale (MADRS)
timeFrame: Post-MRI scan at follow up visit 24 hours
measure: Self-reported rumination related to negative affect as measured by Montgomery-Asberg Depression Rating Scale (MADRS)
timeFrame: Post-MRI scan at follow up visit day 7
measure: Self-reported rumination related to negative affect as measured by Montgomery-Asberg Depression Rating Scale (MADRS)
timeFrame: Post-MRI scan at follow up visit day 30
Other outcomes:
Locations:
city: New York
country: United States
facility: Icahn School Of Medicine at Mount Sinai
state: New York
Study officials:
affiliation: Icahn School of Medicine at Mount Sinai
name: Yael Jacob, PhD
role: PRINCIPAL_INVESTIGATOR
References: